1Tutor, Dept. of Pharmacology, D.D. Medical College, Tiruvallur, Chennai
2Tutor, Dept. of Pharmacology, Saraswathi Institute of Medical Sciences, Hapur, Ghaziabad Dist, Uttar Pradesh
3Associate Professor, Dept. of Forensic Medicine, D.D. Medical College, Tiruvallur, Chennai
4Professor, Dept of Microbiology, D.D. Medical College, Tiruvallur, Chennai
*Corresponding author: S V S D N A Nagesh, Tutor, Dept of Pharmacology, D.D. Medical College, Tiruvallur, Chennai. Email: simhadrii117@gmail.com Contact no: +91 9390010182, +918825871667
Online published on 23 January, 2014.
Hyperlipidaemia results from a disorder in the synthesis and degradation of plasma lipoproteins. Dyslipidaemias have genetic and other causes, and are often associated with high fat diet. The lipids that are of relevance in hyperlipidaemias are cholesterol, an essential component of cell membranes and a precursor of steroid hormone synthesis, and triglycerides, an important energy source. They are transported in the blood as lipoproteins. This study involved 120 patients (both male and female) aged between 30 to 80 years, presenting for treatment in the medical outpatient department of GSL General Hospital. The patients were divided into two groups namely Group A and Group B. Group A patients are those who are taking Atorvastatin 10mg with Fenofibrate 160mg and Group B patients are those who are taking Atorvastatin 10mg and Ezetimibe 10mg as Fixed dose Combinations. After thoroughly analyzing results it was understood the patients with Dyslipidaemias had significantly higher lipid profile levels when compared to post treatment values and their statin combinations therapies resulted in significantly lower mean lipid profile values, which was well correlated with the decrease in total cholesterol, Triglycerides, LDL, VLDL and increase in HDL cholesterol levels.
Dyslipidaemias, Ischemic Heart Disease, Hyperlipidaemias, Fenofibrate, Atorvastatin, Ezetimibe
